Medpace (MEDP) director Dani S. Zander receives stock options grant

Rhea-AI Filing Summary

Medpace Holdings director Dani S. Zander received a stock option grant covering 1,110 shares of common stock at an exercise price of $415.27 per share. This is a compensation-related award, not an open-market trade, and represents a new derivative position for the director.

The option expires on May 15, 2033 and vests on the earlier of the day immediately before the first annual shareholder meeting following the grant date or the first anniversary of the grant date, as long as Zander continues serving on Medpace’s board through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zander Dani S.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,110	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,110 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 1,110 shares Exercise price: $415.27 per share Expiration date: May 15, 2033 +1 more

4 metrics

Option shares granted 1,110 shares Stock option award covering Medpace common stock

Exercise price $415.27 per share Stock option exercise price for Dani S. Zander

Expiration date May 15, 2033 Option term end date

Post-transaction derivative holdings 1,110 options Total options held following reported grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, annual meeting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 415.2700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting regulatory

"the date of the first annual meeting of the Issuer following the date of grant"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

continued service on the board of directors financial

"subject to continued service on the board of directors of the Issuer through the vesting date"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zander Dani S.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$415.27	05/15/2026		A		1,110		(1)	05/15/2033	Common Stock	1,110	$0	1,110	D

Explanation of Responses:

1. The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Dani S. Zander	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medpace (MEDP) report for Dani S. Zander?

Medpace reported that director Dani S. Zander received a grant of stock options for 1,110 shares of common stock. This award is part of director compensation and does not involve an open-market purchase or sale of existing Medpace shares.

How many Medpace (MEDP) shares are covered by Dani S. Zander’s new option?

The newly granted option to Dani S. Zander covers 1,110 shares of Medpace common stock. If fully vested and exercised, the option would allow acquisition of that number of shares at the fixed exercise price stated in the filing.

What is the exercise price and expiration date of Dani S. Zander’s Medpace option?

The option granted to Dani S. Zander has an exercise price of $415.27 per share and an expiration date of May 15, 2033. This defines the price and time window during which the option can be exercised once vested.

When do Dani S. Zander’s Medpace (MEDP) options vest?

The option vests on the earlier of the day immediately before the first annual shareholder meeting following the grant or the first anniversary of the grant date, provided Dani S. Zander continues serving on Medpace’s board until that vesting date.

Is Dani S. Zander’s Medpace Form 4 transaction a stock purchase or sale?

No, the Form 4 reports a grant of stock options, not a purchase or sale in the open market. The transaction code is “A” for grant or award, reflecting equity compensation rather than a discretionary trade in Medpace shares.

How many Medpace derivative securities does Dani S. Zander hold after this grant?

Following the reported transaction, Dani S. Zander holds 1,110 stock options according to the filing’s “total shares following transaction” field. These options relate to Medpace common stock and are held directly as a derivative security position.